April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Serum Insulin-Like Growth Factor-I in Diabetic Retinopathy
Author Affiliations & Notes
  • John F. Payne
    Emory University, Decatur, Georgia
  • Robin Ray
    Emory University, Decatur, Georgia
  • Julia Cleveland
    Biostatistics and Bioinformatics,
    Emory University, Decatur, Georgia
  • Michael Lynn, Sr.
    Biostatistics and Bioinformatics,
    Emory University, Decatur, Georgia
  • Sunil K. Srivastava
    Ophthalmology, Cole Eye Institute, Cleveland, Ohio
  • Footnotes
    Commercial Relationships  John F. Payne, None; Robin Ray, None; Julia Cleveland, None; Michael Lynn, Sr., None; Sunil K. Srivastava, None
  • Footnotes
    Support  Supported in part by a grant to Emory University Eye Center from the Research to Prevent Blindness, Inc., and through a departmental grant from the National Eye Institute, EY06360.
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1266. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      John F. Payne, Robin Ray, Julia Cleveland, Michael Lynn, Sr., Sunil K. Srivastava; Serum Insulin-Like Growth Factor-I in Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1266.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : There is evidence to suggest that insulin-like growth factor I (IGF-I) may play a role in the development of diabetic retinopathy. The purpose of this study was to assess the relationship between serum insulin-like growth factor I (IGF-I) levels and diabetic retinopathy.

Methods: : This is a clinic-based cross sectional study conducted at the Emory Eye Center. A total of 225 subjects were classified into four groups based on diabetes status and retinopathy findings: no diabetes (No DM; n = 99), diabetes with no background diabetic retinopathy (No BDR; n = 42), nonproliferative diabetic retinopathy (NPDR; n = 41), and proliferative diabetic retinopathy (PDR; n = 43). Key exclusion criteria included those with type 1 diabetes and those with a known disorder which may alter IGF-I levels, such as acromegaly. Subjects underwent dilated fundoscopic examination and were tested for hemoglobin A1c, serum creatinine, and IGF-I between December 2009 and March 2010. IGF-I levels were measured via an immunoassay which had been calibrated against the new World Health Organization standard.

Results: : Amongst the groups, there was no statistical difference in age, race, or sex. There was a significant difference between the groups in body mass index, presence of macrovascular disease, duration of diabetes, hemoglobin A1c, insulin use, and serum creatinine. Overall, diabetic subjects had similar IGF-I levels compared to non-diabetic subjects (117.6 µg/L versus 122.0 µg/L, p = 0.497). The mean IGF-I levels for the groups were as follows: No DM = 122.0 µg/L, No BDR = 115.4 µg/L, NPDR = 118.3 µg/L, PDR = 119.1 µg/L. There was no significant difference in IGF-I levels amongst the study groups (p = 0.897). Amongst the diabetic groups, IGF-I levels were similar amongst insulin-dependent subjects and noninsulin-dependent subjects (116.8 µg/L versus 118.2 µg/L, p = 0.876). Univariate analysis of the IGF-I levels demonstrated statistical significance in regards to age (p = 0.002), body mass index (p = 0.008) and race (p = 0.040).

Conclusions: : This study found no association between serum IGF-I levels and diabetic retinopathy and suggests that IGF-I is not a risk factor for the development of PDR.

Keywords: diabetic retinopathy • growth factors/growth factor receptors • clinical (human) or epidemiologic studies: risk factor assessment 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.